Circulating Tumor Cells (CTC) Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)
Circulating Tumor Cells (CTC) Market Analysis:
During the forecast period of 2022–2027, it is anticipated that the circulating tumor cells (CTC) market will exhibit a compound annual growth rate (CAGR) of 9.5%. The COVID-19 pandemic had a global impact on healthcare systems, resulting in the disruption of routine care in numerous healthcare facilities. This exposed cancer patients, who are already vulnerable, to significant risks. A study titled “Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study” conducted in September 2020, involving 356 centers from 54 countries across six continents, reported that 716,979 new cancer patients are served by these centers annually. The majority of these centers (88.2%) faced challenges in delivering care during the pandemic. The reasons for this included a preemptive strategy of reducing services (55.34%), an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). These disruptions in cancer care, such as reduced chemotherapy and radiotherapy services and ongoing research and development studies, have impacted the market growth.
Furthermore, a study titled “Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer,” published in September 2021, evaluated the effect of COVID-19-induced lockdown on newly diagnosed colorectal cancer cases through circulating tumor DNA. The study reported that the tumor burden in patients who received a diagnosis after the lockdown was significantly higher compared with those who were diagnosed before the lockdown. This study indicates that the tumor burden increased significantly during COVID-19, thereby dramatically impacting the market growth.
Get the free sample report of the Circulating Tumor Cells Market
Comments
Post a Comment